Rakesh K. Jain (born 1950) is the Andrew Werk Cook Professor of Tumor Biology director of the E. L. Steele Laboratories at Massachusetts General Hospital in the Harvard Medical School.
He spent his 1983-84 sabbatical year as a Guggenheim Fellow in the departments of chemical engineering at MIT, bioengineering at UCSD and radiation oncology at Stanford, and his 1990–91 sabbatical as a Humboldt Senior Scientist-Awardee at the Institute of Pathophysiology of University of Mainz, and the Institute of Experimental Surgery of University of Munich.
[6][7] He is most celebrated for proposing a new principle – normalization of vasculature – for treatment of malignant and non-malignant diseases characterized by abnormal vessels that afflict more than 500 million people worldwide.
[8][9][10] This concept has fundamentally changed the thinking of scientists and clinicians about how antiangiogenic agents work, and how to combine them optimally with other therapies to improve the treatment outcome in patients.
[11] In 2015, Jain received honorary doctorates from Duke University, KU Leuven, Belgium and IIT-Kanpur, India.